| Prev Close | 61.45 |
| Open | 62.52 |
| Day Low/High | 62.31 / 63.30 |
| 52 Wk Low/High | 53.63 / 71.70 |
| Volume | 5.82M |
Astrazeneca PLC Sponsored ADR (AZN)
63.14
1.69
2.75
NASDAQ
| Exchange | NASDAQ |
| P/E Ratio | 51.70 |
| Div & Yield | N.A. (N.A) |
If You Can Trade These Markets, You Can Survive in Almost Any Environment
If you are out of step with the marketplace, do not blame the marketplace. Understand that you have failed to adapt.
Where Health Meets Tech: 7 Testing and Diagnostics Stocks to Know
Experts pick their favorite long-term investments in medical diagnostics, testing and laboratory services.
Novavax and Its $1.6 Billion Award Just Got My Attention
The smallish clinical-stage vaccine company looks like a trade, not an investment, and might be approached as an option play.
Q2 Earnings Expectations, Phase 3 Vaccine Clinical Trials, Unemployment Numbers
What if the market is simply pricing in a quarter that had already been priced out?
AstraZeneca Has Its Act and Its Charts 'Together'
Let's review the charts and indicators.
Jim Cramer: Are You a Star Player? Let's Put It to the Test
Do you know what a company does, does it do it well, and is there anything going on that could change the trajectory?
Warp Speed for 5 Vaccine Candidates, Watching KLA Corp, Trading Thoughts
The administration will provide increased financial support to 5 pharmas working on Covid vaccines, and we must keep an eye on price action in this uncertain market.
Merck Is All In With a Threefold Approach to Covid-19
I've been long Merck for a long time, since way before this pandemic became part of our lives.
Tight Trading Ranges, China News, Amazon 'Prime Day'
A look at those stocks likely to lead in the short- and long-term, the headlines out of China and Hong Kong, and the import of fiscal stimulus.
The Reasons to Be in AbbVie: Valuation, Dividend Yield, Confidence in Guidance
I have always liked the aggressive management.
Genprex Is Soaring - And There's a One Word Reason Why
The small biotech's market cap sits at $125 million, the low end of what I believe is fair.
Earnings in Full Swing, Workplace Evolution, Fed Day
There was a mild increase in trading volume at the New York Stock Exchange, but it was a rotational shift.
AstraZeneca Could Pause a While Before Challenging the Old Highs
Let's review the charts and indicators.
3 Strong Long-Term Buys for Uncertain Times
These pharmaceutical names have what it takes amid the current crisis and for the long run.
Amazon vs. Microsoft, Assessing the Virus, Sticking Up for Judy Shelton
Fed repo policy changes confirm that external issues are having only a small impact on U.S. economic performance.
Why AbbVie Looks Like a Bargain at These Levels
Nobody in AbbVie right now is in it for the past performance.
Genprex: The Bad and the Good of Capital Raises
For those who love a roll of the dice, GNPX may be worth a closer look.
3 Powerhouse Pharma Stock Favorites
These healthcare stalwarts look attractive for growth and income.
Jim Cramer: Drug Stocks Are Too Cheap
These stocks are priced for total imperfection. That's just what you want.
Jim Cramer: Demand Is Driving This Market to All-Time Highs
The stocks of many companies anticipated a more stringent series of tariffs and we didn't get them.
Amgen Adds Celgene's Otezla to Bolster Pipeline at Pricey Valuation
Amgen is finally making an expected splash out of its cash pile, but questions are abounding about the cost paid for Celgene's Otezla.
5 Favorites for Biotech Stock Buyers
For those with a long-term horizon, here are some top picks.
Big Pharma Sees Pockets of Recent Insider Buying
AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.
Mylan Jumps on Deal With Pfizer to Form New Company
Pfizer will combine its off-patent drug business with Mylan in the as-yet-to-be-named new company.
3 Trends Driving This Earnings Season
With a third of S&P 500 stocks having reported, these 3 trends are coming to the fore.
High Flyers and Low Flyers
Equities are a bit higher across the board since our last update. Homebuilders continue to be in the green as 30-year mortgage rates hover near three-year lows. This is starting to have an effect as purchase application demand has posted its biggest...
Now at the Plate, Your Pinch Hitter, Bret Jensen
I am happy to be sitting back in for Doug Kass on the Daily Diary. I look forward to an active live chat arena today. We certainly have a lot of potential discussion topics. Second-quarter earnings reports will continue to hit the wires in a fast an...
Institutional Selling, Europe's Economy, Nvidia Earnings Preview: Market Recon
What trader has never both fallen in love with Nvidia, only to eventually feel the scorn of an angry lover's tortured vengeance?
The New Small Biotechs Heating Up the Medical Cannabis Space
These companies are working to plant their flag in a new landscape.
Takeda Pharmaceutical CEO Talks Big Pharma Trends
One of pharma's biggest CEO's talks M&A action on the exchange.
